Joachim Boos

List of Publications by Year
in descending order

49 papers	1,602 citations	331670 21 h-index	302126 39 g-index
53 all docs	53 docs citations	53 times ranked	2030 citing authors

#	Article	IF	Citations
1	Paediatric and geriatric drug delivery. Expert Opinion on Drug Delivery, 2007, 4, 37-45.	5.0	209
2	Level of activity in children undergoing cancer treatment. Pediatric Blood and Cancer, 2009, 53, 438-443.	1.5	116
3	Pegylated asparaginase (OncasparTM) in children with ALL: drug monitoring in reinduction according to the ALL/NHL-BFM 95 protocols. British Journal of Haematology, 2000, 110, 379-384.	2.5	113
4	Pharmacokinetics of native Escherichia coli asparaginase (Asparaginase medac) and hypersensitivity reactions in ALL-BFM 95 reinduction treatment. British Journal of Haematology, 2001, 114, 794-799.	2.5	83
5	Analytical validation of a microplate reader-based method for the therapeutic drug monitoring of l-asparaginase in human serum. Analytical Biochemistry, 2002, 309, 117-126.	2.4	76
6	Improved 6â€year overall survival in <scp>AT</scp>/<scp>RT</scp> â€“ results of the registry study Rhabdoid 2007. Cancer Medicine, 2016, 5, 1765-1775.	2.8	73
7	Age and DNA methylation subgroup as potential independent risk factors for treatment stratification in children with atypical teratoid/rhabdoid tumors. Neuro-Oncology, 2020, 22, 1006-1017.	1.2	72
8	The toxicity of very prolonged courses of PEGasparaginase or Erwinia asparaginase in relation to asparaginase activity, with a special focus on dyslipidemia. Haematologica, 2014, 99, 1716-1721.	3.5	66
9	Comparison of selfâ€reported physical activity in children and adolescents before and during cancer treatment. Pediatric Blood and Cancer, 2014, 61, 1023-1028.	1.5	62
10	Experience of barriers and motivations for physical activities and exercise during treatment of pediatric patients with cancer. Pediatric Blood and Cancer, 2014, 61, 1632-1637.	1.5	60
11	Therapeutic drug monitoring of doxorubicin in paediatric oncology using capillary electrophoresis. Electrophoresis, 1998, 19, 2939-2943.	2.4	51
12	Peak plasma concentrations of doxorubicin in children with acute lymphoblastic leukemia or non-Hodgkin lymphoma. Cancer Chemotherapy and Pharmacology, 2002, 49, 133-141.	2.3	45
13	Sports in Pediatric Oncology. Journal of Pediatric Hematology/Oncology, 2014, 36, 85-90.	0.6	44
14	Motor performance in children and adolescents with cancer at the end of acute treatment phase. European Journal of Pediatrics, 2015, 174, 791-799.	2.7	40
15	The effect of individualized exercise interventions during treatment in pediatric patients with a malignant bone tumor. Supportive Care in Cancer, 2013, 21, 1629-1636.	2.2	35
16	A population pharmacokinetic model for pegylatedâ€asparaginase in children. British Journal of Haematology, 2010, 148, 119-125.	2.5	32
17	Asparagine levels in the cerebrospinal fluid of children with acute lymphoblastic leukemia treated with pegylated-asparaginase in the induction phase of the AIEOP-BFM ALL 2009 study. Haematologica, 2019, 104, 1812-1821.	3.5	32
18	Pre-existing antibodies against polyethylene glycol reduce asparaginase activities on first administration of pegylated <i>E. coli</i> asparaginase in children with acute lymphocytic leukemia. Haematologica, 2022, 107, 49-57.	3.5	26

#	Article	IF	Citations
19	Pharmacology of all-trans-retinoic acid in children with acute promyelocytic leukemia. Medical and Pediatric Oncology, 2003, 40, 293-301.	1.0	25
20	Pharmacokinetic and pharmacodynamic study of doxorubicin in children with cancer: results of a â€œEuropean Pediatric Oncology Off-patents Medicines Consortiumâ€•trial. Cancer Chemotherapy and Pharmacology, 2016, 78, 1175-1184.	2.3	25
21	Pharmacokinetics of intravenous paracetamol in children and adolescents under major surgery. European Journal of Clinical Pharmacology, 2005, 60, 883-888.	1.9	24
22	Age-Dependent Pharmacokinetics of Doxorubicin in Children with Cancer. Clinical Pharmacokinetics, 2015, 54, 1139-1149.	3.5	23
23	One in Four Questioned Children Faces Problems Regarding Reintegration Into Physical Education at School After Treatment for Pediatric Cancer. Pediatric Blood and Cancer, 2016, 63, 737-739.	1.5	23
24	Objectively measured versus self-reported physical activity in children and adolescents with cancer. PLoS ONE, 2017, 12, e0172216.	2.5	21
25	Pharmacokinetics of daunorubicin and daunorubicinol in infants with leukemia treated in the interfant 99 protocol. Pediatric Blood and Cancer, 2010, 54, 355-360.	1.5	20
26	Feasibility and effects of a home-based intervention using activity trackers on achievement of individual goals, quality of life and motor performance in patients with paediatric cancer. BMJ Open Sport and Exercise Medicine, 2018, 4, e000322.	2.9	17
27	Adverse Events During Supervised Exercise Interventions in Pediatric Oncologyâ€”A Nationwide Survey. Frontiers in Pediatrics, 2021, 9, 682496.	1.9	17
28	Minimization of the Preanalytical Error in Plasma Samples for Pharmacokinetic Analyses and Therapeutic Drug Monitoring - Using Doxorubicin as an Example. Therapeutic Drug Monitoring, 2011, 33, 766-771.	2.0	16
29	Population Pharmacokinetics to Model the Time-Varying Clearance of the PEGylated Asparaginase OncasparÂ® in Children with Acute Lymphoblastic Leukemia. European Journal of Drug Metabolism and Pharmacokinetics, 2017, 42, 955-963.	1.6	16
30	Therapeutic Drug Monitoring of Asparaginase Activityâ€”Method Comparison of MAAT and AHA Test Used in the International AIEOP-BFM ALL 2009 Trial. Therapeutic Drug Monitoring, 2018, 40, 93-102.	2.0	16
31	Asparaginase activities during intensified treatment with pegylatedE. coliasparaginase in adults with newly-diagnosed acute lymphoblastic leukemia. Leukemia and Lymphoma, 2020, 61, 138-145.	1.3	16
32	A germ line mutation in cathepsin B points toward a role in asparaginase pharmacokinetics. Blood, 2014, 124, 3027-3029.	1.4	12
33	Targeting hedgehog signaling pathway in pediatric tumors: in vitro evaluation of SMO and GLI inhibitors. Cancer Chemotherapy and Pharmacology, 2016, 77, 495-505.	2.3	12
34	Letters to the Editor. American Journal of Physiology - Cell Physiology, 1998, 274, C1185-C1185.	4.6	11
35	Therapeutic Drug Monitoring of Asparaginase: Intra-individual Variability and Predictivity in Children With Acute Lymphoblastic Leukemia Treated With PEG-Asparaginase in the AIEOP-BFM Acute Lymphoblastic Leukemia 2009 Study. Therapeutic Drug Monitoring, 2020, 42, 435-444.	2.0	11
36	Reduced vs. standard dose native E. coli-asparaginase therapy in childhood acute lymphoblastic leukemia: long-term results of the randomized trial Moscowâ€“Berlin 2002. Journal of Cancer Research and Clinical Oncology, 2019, 145, 1001-1012.	2.5	10

#	Article	IF	Citations
37	Bioanalysis of doxorubicin aglycone metabolites in human plasma samplesâ€“implications for doxorubicin drug monitoring. Scientific Reports, 2020, 10, 18562.	3.3	9
38	Population Pharmacokinetics of NativeEscherichia ColiAsparaginase. Pediatric Hematology and Oncology, 2012, 29, 154-165.	0.8	8
39	Can we optimise doxorubicin treatment regimens for children with cancer? Pharmacokinetic simulations and a Delphi consensus procedure. BMC Pharmacology & Toxicology, 2020, 21, 37.	2.4	7
40	Population Pharmacokinetics of PEGylated Asparaginase in Children with Acute Lymphoblastic Leukemia: Treatment Phase Dependency and Predictivity in Case of Missing Data. European Journal of Drug Metabolism and Pharmacokinetics, 2021, 46, 289-300.	1.6	6
41	Towards a Model-Based Dose Recommendation for Doxorubicin in Children. Clinical Pharmacokinetics, 2017, 56, 215-223.	3.5	5
42	Use of PEG-asparaginase in the treatment of patients with solid tumors. Cancer Chemotherapy and Pharmacology, 2001, 48, 421-422.	2.3	4
43	Low dose-high dose: what is the right dose? Pharmacokinetic modeling of etoposide. Cancer Chemotherapy and Pharmacology, 2002, 49, 303-308.	2.3	4
44	Preclinical Evaluation of Combined Topoisomerase and Proteasome Inhibition Against Pediatric Malignancies. Anticancer Research, 2018, 38, 3977-3984.	1.1	3
45	A Prospective Study On Drug Monitoring Of Pegasparaginase and Erwinia Asparaginase and Asparaginase Antibodies In Pediatric Acute Lymphoblastic Leukemia. Blood, 2013, 122, 2634-2634.	1.4	3
46	Impact of Antibodies Against Polyethylene Glycol on the Pharmacokinetics of PEGylated Asparaginase in Children with Acute Lymphoblastic Leukaemia: A Population Pharmacokinetic Approach. European Journal of Drug Metabolism and Pharmacokinetics, 2022, 47, 187-198.	1.6	2
47	Toxicity of Very Prolonged Pegasparaginase and Erwinia Asparaginase Courses in Relation to Asparaginase Activity Levels with a Special Focus on Dyslipidemia. Blood, 2014, 124, 2256-2256.	1.4	1
48	The Bone Marrow Niche of Patients with Acute Lymphoblastic Leukemia Produces No Increased Asparagine Levels In Vivo That May Lead to Clinical Asparaginase Resistance. Blood, 2011, 118, 1505-1505.	1.4	0
49	A Germline Mutation in Cathepsin B in a Child with ALL Points towards a Key Role for This Enzyme in L-Asparaginase Pharmacokinetics.. Blood, 2012, 120, 2458-2458.	1.4	0